*ST Shuangcheng: Announcement of Hainan Shuangcheng Pharmaceutical Co., Ltd. on the election of employee representative directors
Securities code: 002693 Securities abbreviation: *ST Shuangcheng Announcement number: 2026-003
Hainan Shuangcheng Pharmaceutical Co., Ltd.
Announcement on the Election of Employee Representative Directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
The term of the fifth board of directors of Hainan Shuangcheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has expired. In order to ensure the normal operation of the board of directors, in accordance with the relevant provisions of the "Company Law" and the "Articles of Association", the company held a company employee representative meeting in the company conference room on January 8, 2026.
After careful deliberation by all employee representatives present at the meeting, and fully promoting democracy, Mr. LI JIANMING was unanimously elected as the employee representative director of the company's sixth session of the Board of Directors (see the attachment for resume details). Mr. LI JIANMING, the employee representative director, will form the company's sixth board of directors together with the non-employee representative directors elected at the company's first extraordinary shareholders' meeting in 2026. The term will be from the date of review and approval by the employees' representative meeting to the expiration date of the sixth board of directors.
After the completion of the election of employee representative directors, the total number of directors who concurrently serve as senior managers of the company and employee representatives in the company's sixth board of directors does not exceed one-half of the total number of directors of the company.
Announcement is hereby made.
Board of Directors of Hainan Shuangcheng Pharmaceutical Co., Ltd.
January 9, 2026
Attachment: Resume of Employee Representative Director
Mr. LI JIANMING, American nationality, born in 1956, holds a PhD in biochemistry and an MBA, and is a US Patent Registrar. After receiving his doctorate in the United States, he successively worked in the Department of Pharmacology at Yale University School of Medicine, the National Cancer Institute, and the U.S. Food and Drug Administration for the approval of new drugs and new biological drugs. In 2006, he joined Pfizer in the United States as deputy director of regulatory registration, responsible for the research and development and approval of new drugs. He joined Shuangcheng Pharmaceutical in July 2013 and served as the company's deputy general manager, responsible for managing R&D and international affairs. He is currently the company's director and general manager.
As of the announcement date, Mr. LI JIANMING directly held 1,150,000 shares of the company, accounting for 0.28% of the company's total share capital. There is no related relationship with the company’s controlling shareholder and actual controller, and it has no relationship with other shareholding shareholders. There is no related relationship among shareholders with more than 5% and other directors and senior managers of the company. There is no situation that prohibits them from serving as directors or senior managers of the company as stipulated in the "Company Law" and other relevant laws and regulations. They comply with the requirements of the "Company Law" and other relevant laws and regulations and the "Articles of Association" and have not been subject to the China Securities Regulatory Commission and other relevant regulations. Penalties imposed by the department and sanctions imposed by the Shenzhen Stock Exchange; there have been no cases of being investigated by judicial authorities for suspected crimes or being investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations without a clear conclusion; they have not been publicized by the China Securities Regulatory Commission on the illegal and untrustworthy information public inquiry platform in the securities and futures markets, or have been included in the list of dishonest persons subject to enforcement by the people's court.